Reliable real-time analytical control of monoclonal antibodies chemotherapies preparations on Multispec® automaton;Contrôle rapide et fiable des préparations de chimiothérapies à base d'anticorps monoclonaux à l'aide de l'automate Multispec

Annales Pharmaceutiques Francaises

Volumn 68, Issue 3, 2010, Pages 163-177

  Bazin, C ^a   Vieillard, V ^a   Astier, A ^a,b   Paul, M ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b FACULTÉ DE MÉDECINE   (France)

Author keywords

Chemotherapies; Control; Infrared; Monoclonal antibodies; Multispec

Indexed keywords

MONOCLONAL ANTIBODY; ANTINEOPLASTIC AGENT;

ANALYTIC METHOD; ARTICLE; CHEMOTHERAPY; DRUG CONTROL; DRUG MARKETING; INFRARED SPECTROSCOPY; PREDICTIVE VALIDITY; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; RELIABILITY; ULTRAVIOLET SPECTROSCOPY; AUTOMATION; COMPUTER SYSTEM; REPRODUCIBILITY; ULTRAVIOLET SPECTROPHOTOMETRY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUTOMATION; COMPUTER SYSTEMS; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 77953618358     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2010.03.008     Document Type: Article

References (44)

1. Gallelli J. Issues and risks associated with handling antineoplastic drugs. J Pharm Pract 1991, 4:72-76.
2. Valanis B.G., Vollmer W.M., Labuhn K.T., Glass A.G. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm 1993, 50:455-462.
3. Power L.A., Anderson R.W., Cortopassi R., Gera J.R., Lewis R.M. Update on safe handling of hazardous drugs: the advice of experts. Am J Hosp Pharm 1990, 47:1050-1060.
4. DeMeo M.P., Merono S., DeBaille A.D., Botta A., Laget M., Guiraud H., et al. Monitoring exposure of hospital personnel handling cytostatic drugs and contaminated materials. Int Arch Occup Environ Health 1995, 66:363-368.
5. Sessink P.J., Wittenhorst B.C., Anzion R.B., Bos R.P. Exposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures. Arch Environ Health 1997, 52:240-244.
6. Sessink P.J., Boer K.A., Scheefhals A.P., Anzion R.B., Bos R.P. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health 1992, 64:105-112.
7. Pethran A., Schierl R., Hauff K., Grimm C.H., Boos K.S., Nowak D. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. Int Arch Occup Environ Health 2003, 76:5-10.
8. Ziegler E., Mason H.J., Baxter P.J. Occupational exposure to cytotoxic drugs in two UK oncology wards. Occup Environ Med 2002, 59:608-612.
9. Martin F., Legat C., Coutet J., Bracco-Nolin C.H., Jacquet M., Woronoff-Lemsi M.C., et al. Maîtrise des erreurs de préparation des médicaments anticancéreux en unité centralisée: de l'épidémiologie à l'assurance qualité. Bull Cancer 2004, 91:972-976.
10. Baldo P., Bertola A., Basaglia G., Moneghini M., Sorio R., Zibardi E., et al. A centralized pharmacy unit for cytotoxic drugs in accordance with Italian legislation. J Eval Clin Pract 2007, 13:265-271.
11. Cazin J.L., Gosselin P. Implementing a multiple-isolator unit for centralized preparation of cytotoxic drugs in a cancer center pharmacy. Pharm World Sci 1999, 21:177-183.
12. ASHP guidelines on quality assurance for pharmacy-prepared sterile products. American Society of Health System Pharmacists. Am J Health Syst Pharm 2000;57:1150-69.
13. Favier M., Hansel S., Bressolle F. Preparing cytotoxic agents in an isolator. Am J Hosp Pharm 1993, 50:2335-2339.
14. Tillett L. Barrier isolators as an alternative to a cleanroom. Am J Health Syst Pharm 1999, 56:1433-1436.
15. Augry F., Iltis A., Letellier D. Évaluation de l'économie réalisée au sein d'une unité centralisée de fabrication des médicaments cytotoxiques destinées à la voie parentérale. J Pharm Clin 1996, 15:12-14.
16. Favier M., Fliche E., Bressolle F. Economic benefit of a centralized reconstitution unit of cytotoxic drug in isolator. J Oncol Pharm Pract 1996, 2:182-185.
17. Legat C., Limat S., Coutet J., D'attoma F., Jacquet M., Woronoff-Lemsi M.C. Impact économique de la préparation centralisée des médicaments anticancéreux. J Pharm Clin 2003, 22:181-185.
18. Limat S., Madroszyk-Flandin A., Nallet G., Dessard-Choupay G., Jacquet M., Woronoff-Lemsi M.C. Risque iatrogène lié à la prescription des médicaments anticancéreux. Oncologie 2002, 4:203-208.
19. Ritter H., Trissel L.A., Anderson R.W., Moyer L.M., Morales J.S. Electronic balance as quality assurance for cytotoxic drug admixtures. Am J Health Syst Pharm 1996, 53:2318-2320.
20. Basuyau F., Brunelle P. Comparaison de deux mesures physiques rapides pour le contrôle de la dose des préparations injectables de médicaments anticancéreux avant administration: application au 5-fluorouracile. J Pharm Clin 2000, 19:5-9.
21. Havard L., Bonan B., Huen J.M., Roche Y., Prognon P. Le contrôle de qualité en unité centralisée de reconstitution des cytotoxiques: mythe ou réalité ?. STP Pharma Prat 2005, 15:148-160.
22. Pelus E., Dellanegra M., Charlety D., Magnin N., Petit N., Meylan I. Unité de préparation centralisée des cytotoxiques: de la mise en place à l'assurance-qualité. J Pharm Clin 1998, 17:97-102.
23. Watt S., Antier D., Jacques V., Grassin J. New program for quality control of cytotoxics manufactured in centralised unit. J Pharm Clin 2002, 21:179-182.
24. Bonan B., Martelli N., Berhoune M., Maestroni M.L., Havard L., Prognon P. The application of hazard analysis and critical control points and risk management in the preparation of anticancer drugs. Int J Qual Health Care 2009, 21:44-50.
25. Escoms M.C., Cabanas M.J., Oliveras M., Hidalgo E., Barroso C. Errors evolution and analysis in antineoplastic drug preparation during 1 year. Pharm World Sci 1996, 18:178-181.
26. Flynn E.A., Pearson R.E., Barker K.N. Observational study of accuracy in compounding i.v. admixtures at five hospitals. Am J Health Syst Pharm 1997, 54:904-912.
27. Breton G, Pouliquen AL, François C, Clément I, Daronat M. Méthodes de contrôle des préparations de chimiothérapies: Qu'en est-il ? (résumé). Journées de l'APHIF: Paris; 2008, (abstract 46).
28. Ripoche N., Baumgartner P., Audeval C., Rochard S. Feasibility study of extemporaneous control of cytotoxic preparations: tests with an innovating spectrometer coupling UV/visible and IR detections. Eur J Hosp Pharm Pract 2009, 15:28-31.
29. Therapeutic monoclonal antibodies Report 2008-2023. 2008, Thomson Reuteurs.
30. Pavlou A.K., Belsey M.J. The therapeutic antibodies market to 2008. Eur J Pharm Biopharm 2005, 59:389-396.
31. Chames P., Van Regenmortel M., Weiss E., Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009, 157:220-233.
32. Pelton J.T., McLean L.R. Spectroscopic methods for analysis of protein secondary structure. Anal Biochem 2000, 277:167-176.
33. Lahlou A., Blanchet B., Carvalho M., Paul M., Astier A. Mechanically-induced aggregation of the monoclonal antibody cetuximab. Ann Pharm Fr 2009, 67:340-352.
34. Kupfer M., Scriba G., Hartmann M. Stability of alemtuzumab in infusion-bags. Pharmazie 2009, 64:622-623.
35. Bakri S.J., Snyder M.R., Pulido J.S., McCannel C.A., Weiss W.T., Singh R.J. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 2006, 26:519-522.
36. Ornek K., Karahan Z.C., Ergin A., Tekeli A., Tekeli O. Bevacizumab sterility in multiple doses from a single-use vial. Ann Pharmacother 2008, 42:1425-1428.
37. Paul M., Lahlou A., Carvalho M., Blanchet B., Astier A. Thermal stability of two monoclonal antibodies: cetuximab and bevacizumab. EJOP 2008, 2:37.
38. Wang W., Singh S., Zeng D.L., King K., Nema S. Antibody structure, instability and formulation. J Pharm Sci 2007, 96:1-26.
39. ICH text on validation of analytical procedures: methodology. ICH Harmonised Tripartite Guideline 1996;4:1-8.
40. Barth A. Infrared spectroscopy of proteins. Biochim Biophys Acta 2007, 1767:1073-1101.
41. Levillain P., Fompeydie D. Spectrophotométrie dérivée: intérêt, limites et applications. Analusis 1986, 14:1-20.
42. Joseph-Charles J., Bertucat M., Levillain P. Intérêt de la spectrophotométrie dérivée pour l'identification d'une substance. Bull Soc Pharm Bordeaux 1997, 136:56-76.
43. Dossier du CNHIM, anticancéreux: utilisation pratique. 6e ed. 2008.
44. Fischer S., Hoernschemeyer J., Mahler H.C. Glycation during storage and administration of monoclonal antibody formulations. Eur J Pharm Biopharm 2008, 70:42-50.